ECSP21023404A - Inhibidores de pde4 que contienen boro - Google Patents

Inhibidores de pde4 que contienen boro

Info

Publication number
ECSP21023404A
ECSP21023404A ECSENADI202123404A ECDI202123404A ECSP21023404A EC SP21023404 A ECSP21023404 A EC SP21023404A EC SENADI202123404 A ECSENADI202123404 A EC SENADI202123404A EC DI202123404 A ECDI202123404 A EC DI202123404A EC SP21023404 A ECSP21023404 A EC SP21023404A
Authority
EC
Ecuador
Prior art keywords
containing boron
pde4 inhibitors
inhibitors containing
pde4
formula
Prior art date
Application number
ECSENADI202123404A
Other languages
English (en)
Inventor
Yasheen Zhou
Matthew Alexander Perry
Rubben Federico Torella
David Christopher Limburg
Thean Yeow Yeoh
Jacob John Plattner
David Clive Blakemore
Tsutomu Akama
Martins Sunday Oderinde
Robert Toms Jacobs
Peter Jones
Joseph Walter Strohbach
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=68136492&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP21023404(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer filed Critical Pfizer
Publication of ECSP21023404A publication Critical patent/ECSP21023404A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente invención se refiere a compuestos que contienen boro de la Fórmula (I) X-Y-Z Fórmula (I) que inhiben la fosfodiesterasa 4 (PDE4). La invención también comprende composiciones farmacéuticas que contienen estos compuestos y métodos para tratar enfermedades, afecciones o trastornos que mejoran mediante la inhibición de PDE4.
ECSENADI202123404A 2018-10-05 2021-04-05 Inhibidores de pde4 que contienen boro ECSP21023404A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862741868P 2018-10-05 2018-10-05
US201962889599P 2019-08-21 2019-08-21

Publications (1)

Publication Number Publication Date
ECSP21023404A true ECSP21023404A (es) 2021-05-31

Family

ID=68136492

Family Applications (1)

Application Number Title Priority Date Filing Date
ECSENADI202123404A ECSP21023404A (es) 2018-10-05 2021-04-05 Inhibidores de pde4 que contienen boro

Country Status (30)

Country Link
US (3) US10946031B2 (es)
EP (1) EP3861001B1 (es)
JP (1) JP7048823B2 (es)
KR (1) KR102576125B1 (es)
CN (1) CN113166177B (es)
AU (1) AU2019351960B2 (es)
BR (1) BR112021005870B1 (es)
CA (1) CA3114702C (es)
CL (1) CL2021000843A1 (es)
CO (1) CO2021003928A2 (es)
CR (1) CR20210163A (es)
CU (1) CU20210023A7 (es)
DK (1) DK3861001T3 (es)
DO (1) DOP2021000055A (es)
EC (1) ECSP21023404A (es)
ES (1) ES2974208T3 (es)
FI (1) FI3861001T3 (es)
GE (2) GEAP202215599A (es)
IL (1) IL282083B2 (es)
MA (1) MA53808A (es)
MX (1) MX2021003871A (es)
NI (1) NI202100020A (es)
PE (1) PE20211546A1 (es)
PH (1) PH12021550743A1 (es)
PY (1) PY1983118A (es)
SG (1) SG11202102674RA (es)
TW (1) TWI764052B (es)
UY (1) UY38400A (es)
WO (1) WO2020070651A1 (es)
ZA (1) ZA202101822B (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA53395A (fr) 2018-07-24 2021-06-02 Otsuka Pharma Co Ltd Composés hétérobicycliques pour inhiber l'activité de shp2
GB201911928D0 (en) 2019-08-20 2019-10-02 Otsuka Pharma Co Ltd Pharmaceutical compounds
CA3191886A1 (en) * 2020-08-20 2022-02-24 Pfizer Inc. Stable topical formulations of 1(r)-4-(5-(4-methoxy-3-propoxyphenyl)pyridin-3-yl)-1,2-oxaborolan-2-ol
WO2022043936A1 (en) 2020-08-31 2022-03-03 Pfizer Inc. Methods of protecting rna
EP4748445A3 (en) 2020-12-25 2026-06-03 Reistone Biopharma Company Limited Borate derivative and uses thereof
TW202404610A (zh) 2022-06-24 2024-02-01 大陸商瑞石生物醫藥有限公司 一種硼酸酯衍生物的結晶、其製備方法及用途
TW202408483A (zh) * 2022-06-24 2024-03-01 大陸商瑞石生物醫藥有限公司 一種硼酸酯衍生物的可藥用鹽、其結晶形式及用途
GB202306663D0 (en) 2023-05-05 2023-06-21 Union Therapeutics As Combination therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9411587D0 (en) 1994-06-09 1994-08-03 Zeneca Ltd Compound, composition and use
PT901786E (pt) 1997-08-11 2007-08-07 Pfizer Prod Inc Disperções farmacêuticas sólidas com biodisponibilidade melhorada
ES2872962T3 (es) * 2005-02-16 2021-11-03 Anacor Pharmaceuticals Inc Boronoftalidas para uso terapéutico
JO3598B1 (ar) 2006-10-10 2020-07-05 Infinity Discovery Inc الاحماض والاسترات البورونية كمثبطات اميد هيدروليز الحامض الدهني
JP5745279B2 (ja) 2008-01-09 2015-07-08 アナコール ファーマシューティカルズ,インコーポレイテッド 抗炎症剤としてのホウ素含有小分子
WO2009111676A2 (en) 2008-03-06 2009-09-11 Anacor Pharmaceuticals, Inc Boron-containing small molecules as anti-inflammatory agents
EP3246034A1 (en) * 2008-03-06 2017-11-22 Anacor Pharmaceuticals, Inc. Boron-containing small molecules as anti-inflammatory agents
AU2011329485A1 (en) * 2010-11-18 2013-04-18 Glaxo Group Limited Compounds
CA2850263A1 (en) 2011-10-07 2013-04-11 Syngenta Participations Ag Method for protecting useful plants or plant propagation material
WO2014066659A1 (en) * 2012-10-25 2014-05-01 Tetra Discovery Partners, Llc. Heteroaryl inhibitors of pde4
EP2752196A1 (en) 2013-01-03 2014-07-09 Université Bordeaux Segalen Selective nox-1 inhibitor peptides and uses thereof
AR094666A1 (es) 2013-01-30 2015-08-19 Dow Agrosciences Llc Uso de benzoxaborolas como agentes antimicrobianos volátiles en carnes, plantas o partes de plantas
WO2014147009A1 (en) 2013-03-18 2014-09-25 Syngenta Participations Ag Novel microbiocides
AU2014202928B1 (en) 2013-06-05 2014-09-11 Agrofresh Inc. Compounds and compositions
GB201705263D0 (en) * 2017-03-31 2017-05-17 Probiodrug Ag Novel inhibitors
BR112020012651A2 (pt) 2017-12-22 2020-12-01 Ravenna Pharmaceuticals, Inc. compostos derivados de aril-bipiridina amina como inibidores da fosfatidilinositol fosfato quinase, composição farmacêutica compreendendo os mesmos e usos terapêuticos dos ditos compostos

Also Published As

Publication number Publication date
ZA202101822B (en) 2022-08-31
CN113166177B (zh) 2024-09-03
IL282083A (en) 2021-05-31
UY38400A (es) 2020-04-30
TW202027755A (zh) 2020-08-01
DK3861001T3 (da) 2024-01-15
CO2021003928A2 (es) 2021-04-19
BR112021005870B1 (pt) 2024-01-09
FI3861001T3 (fi) 2024-01-03
AU2019351960B2 (en) 2022-07-28
AU2019351960A1 (en) 2021-04-29
CR20210163A (es) 2021-06-24
KR102576125B1 (ko) 2023-09-08
NI202100020A (es) 2021-08-24
US10946031B2 (en) 2021-03-16
US20210069219A1 (en) 2021-03-11
PY1983118A (es) 2021-07-15
EP3861001A1 (en) 2021-08-11
CA3114702C (en) 2023-08-08
US20200108083A1 (en) 2020-04-09
IL282083B1 (en) 2025-01-01
DOP2021000055A (es) 2021-05-16
JP7048823B2 (ja) 2022-04-05
CN113166177A (zh) 2021-07-23
EP3861001B1 (en) 2023-12-13
BR112021005870A2 (pt) 2021-07-27
MX2021003871A (es) 2021-05-27
MA53808A (fr) 2022-01-12
GEP20227442B (en) 2022-11-25
WO2020070651A1 (en) 2020-04-09
PE20211546A1 (es) 2021-08-16
PH12021550743A1 (en) 2021-10-11
KR20210068532A (ko) 2021-06-09
JP2021534222A (ja) 2021-12-09
SG11202102674RA (en) 2021-04-29
GEAP202215599A (en) 2022-08-10
ES2974208T3 (es) 2024-06-26
US11559538B2 (en) 2023-01-24
IL282083B2 (en) 2025-05-01
CU20210023A7 (es) 2021-10-12
CA3114702A1 (en) 2020-04-09
CL2021000843A1 (es) 2021-09-10
TWI764052B (zh) 2022-05-11
US20230148402A1 (en) 2023-05-11

Similar Documents

Publication Publication Date Title
UY38400A (es) Inhibidores de pde4 que contienen boro
MX2020007383A (es) Compuestos de 1,2,4-oxadiazol como inhibidores de las vías de señalización de cd47.
MX2023001917A (es) Inhibidores de la fosfatasa shp2 y metodos para su uso.
UY33245A (es) Tienopirimidinas que contienen un grupo alquilo sustituido para composiciones farmacéuticas
NI201400121A (es) Compuestos de indol e indazol que activan la ampk
JOP20180113B1 (ar) مركبات بيريميدين -2-يل امينو -h1- بيرازول كمثبطات lrrk2 للاستخدام في علاج اضطرابات تنكسية عصبية
PH12020551014A1 (en) Amino-fluoropiperidine derivatives as kinase inhibitor
PH12020551013A1 (en) Oxy-fluoropiperidine derivative as kinase inhibitor
CU20180006A7 (es) Compuestos de indazaol y azaindazol como inhibidores de irak-4
CL2021000683A1 (es) Dioxociclobutenilamino-3-hidroxi-picolinamidas n-sustituidas útiles como inhibidores de ccr6
BR112017006705A2 (pt) inibidores de biossíntese de sulfato de heparan para o tratamento de doenças
MX2016009352A (es) Inhibidores de quinasa a base de quinolina.
EA201590268A1 (ru) Ариллактамные ингибиторы киназы
MX2019008331A (es) Derivados de amino-imidazopiridina novedosos como inhibidores de cinasa de janus y uso farmacéutico de estos.
MX2021014361A (es) Nuevos compuestos para la inhibición de janus quinasa 1.
PH12021550258A1 (en) Cdk8/19 inhibitors
MA42776B1 (fr) Composés utiles pour l'inhibition du ror-gamma-t
UY38133A (es) Nuevos inhibidores de cdk8/19
EA201591369A1 (ru) Новые производные пиримидина в качестве ингибиторов фосфодиэстеразы 10 (pde-10)
SA521430837B1 (ar) مركبات مثبطة لمبادل الصوديوم-الهيدروجين 3
EA202190690A1 (ru) Борсодержащие ингибиторы pde4
CL2020001089A1 (es) Compuestos inhibidores de tirosina cinasa de bruton (btk).
MA39204B1 (fr) Derives hétéroaryles inhibiteurs de vps34 et/ou de p13 pour le traitement de troubles proliferatifs, inflammatoires ou cardiovasculaires
MA44503B1 (fr) Composés de pyrrolotriazine en tant qu'inhibiteurs de tam
EA201891687A9 (ru) Новые замещённые производные цианиндолина в качестве nik-ингибиторов